Key Developments: IDEXX Laboratories Inc (IDXX.O)
83.37USD
22 May 2013
$-2.19 (-2.56%)
$85.56
$85.56
$86.25
$83.34
473,980
421,018
$101.18
$81.31
Latest Key Developments (Source: Significant Developments)
IDEXX Laboratories Inc Lowers FY 2013 Guidance
IDEXX Laboratories Inc announced that for fiscal 2013, it expects revenues to be $1.38 billion to $1.39 billion, organic growth is estimated to be in the range of 7.5% to 8%, as compared with previous guidance of 8% to 9%, reflective of organic growth in the first quarter and an anticipated reduction in capital equipment sales in ensuing quarters from previous guidance. The decrease in expected reported revenue is the result of unfavorable changes in foreign currency exchange rates, reflecting a strengthening of the U.S. dollar relative to other currencies since the date of previous guidance, as well as the reduction in outlook for 2013 organic growth. EPS are expected to be $3.40 to $3.46 on a GAAP and non-GAAP basis. This compares to previous guidance which reflected EPS of $3.47 to $3.57 on a GAAP basis and $3.42 to $3.52 on a non-GAAP basis. EPS on a non-GAAP basis are adjusted to exclude the favorable impact of the retroactive extension of the 2012 federal R&D tax credit and the unfavorable impact of the third-party service provider's bankruptcy. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of 1.401 billion and EPS of $3.54 for fiscal 2013. Full Article
IDEXX Laboratories Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
IDEXX Laboratories Inc announced that for fiscal 2013, it expects revenue to be in the range of $1.405 to $1.42 billion, which represents reported growth of 8.5% to 9.5% relative to 2012. Organic revenue growth is estimated to be in the range of 8% to 9% and is consistent with previous guidance. Earnings per share (EPS) are expected to be $3.47 to $3.57, compared to guidance of $3.37 to $3.47. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of 1.405 billion and EPS of $3.48 for fiscal 2013. Full Article
IDEXX Laboratories Inc Updates On FY 2013 Guidance-Conference Call
IDEXX Laboratories Inc announced that for fiscal 2013, it expects revenues of $1.405 billion to $1.425 billion and earnings per share (EPS) of $3.33 to $3.47. Full Article
IDEXX Laboratories Inc Announces Intention To Modify Distribution Relationship With MWI Veterinary Supply, Inc.
IDEXX Laboratories Inc announced it has agreed with MWI Veterinary Supply, Inc. (MWI) on the terms of a revised distribution relationship under which MWI will continue to sell IDEXX products to veterinary customers in the U.S., and in the future also will be able to sell products that compete with IDEXX's products. Under the new arrangement, which is expected to become effective January 1, 2013, IDEXX will reduce the discount from list price at which it sells its products to MWI. Full Article
IDEXX Laboratories, Inc. Lowers FY 2012 Guidance
IDEXX Laboratories, Inc. announced that for fiscal 2012, it expects revenues to be in the range of $1.30-$1.31 billion, which represents reported growth of 7% to 8% and organic growth of 8% to 9%. The decrease in expected reported revenue compared to previous guidance is due exclusively to unfavorable changes in foreign currency exchange rates, reflecting a strengthening of the U.S. dollar relative to other currencies since the date of previous guidance and EPS to be $3.05 to $3.10, compared to previous guidance of $3.07 to $3.12. The change in EPS guidance is due exclusively to the unfavorable impact of changes in foreign currency exchange rates since the date of previous guidance. Fluctuations in foreign currency exchange rates from current assumptions could have a significant positive or negative impact on actual results of operations for 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.31 billion and EPS of $3.10 for fiscal 2012. Full Article
IDEXX Laboratories, Inc. Reaffirms FY 2012 Revenue Guidance-Conference Call
IDEXX Laboratories, Inc. announced that for fiscal 2012, it expects 8% to 9% organic growth. The Company reported revenues of $1.219 billion in fiscal 2011. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.313 billion for fiscal 2012. Full Article
IDEXX Laboratories, Inc. Raises FY 2012 Guidance-Conference Call
IDEXX Laboratories, Inc. announced that for fiscal 2012, it expects revenue to be in the range of $1.31-$1.32 billion and earnings per share (EPS) to be in the range of $3.07-$3.12. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.30 billion and EPS of $3.10 for fiscal 2012. Full Article
Avacta Group Plc Signs Exclusive Supply Deal With IDEXX Laboratories
Avacta Group Plc announced that Avacta Animal Health has entered into an exclusive agreement with IDEXX Laboratories , to supply reagents for high throughput laboratory testing for C-reactive protein in dogs. Under the terms of the agreement, Avacta will exclusively supply its proprietary diagnostic reagents for use with high-throughput bioanalysers in IDEXX reference laboratories. IDEXX receives global rights to use the diagnostic reagents to provide testing through its companion animal diagnostics services. The supply agreement concerns diagnostic reagents to test for C-reactive protein (CRP) in dogs, for the early detection of acute inflammation or infection. Full Article
IDEXX Laboratories, Inc. Reaffirms FY 2012 Revenue Guidance; Lowers Low End Of Prior FY 2012 EPS Guidance To A Range In Line With Analyst' Estimates
IDEXX Laboratories, Inc. announced that for fiscal 2012, it expects revenues to be $1.30-$1.31 billion, earnings per share (EPS) is expected to be $3.04-$3.10, compared to the previous guidance of $3.00-$3.10. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $1.30 billion and EPS of $3.07 for fiscal 2012. Full Article
IDEXX Laboratories, Inc. Acquires RADIL Reference Laboratory From University Of Missouri
IDEXX Laboratories, Inc. announced that it has acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri for $43 million in cash. Based in Columbia, Missouri, RADIL provides health monitoring and diagnostic testing services to bioresearch customers. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
